Binge drinking and possibly, moderate alcohol intake, may trigger atrial fibrillation. Caffeine intake does not appear to be a trigger; although, some doctors still recommend that patients with atrial ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation. One of the core results from AZALEA-TIMI 71 ...

That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than makes up for the $295 million that Boston Scientific put down to ...

Aberrant activation of the sympathetic nervous system can induce heterogeneous changes with arrhythmogenic potential which can result in atrial tachycardia, atrial tachyarrhythmias and atrial ...

vip.sina.com Objective To determine AF prevalence and gaps in atrial fibrillation (AF) awareness and management in China. Methods We conducted a community-based survey of 47 841 adults (age ≥45 years) ...

Atrial fibrillation (AF) is the most common sustained cardiac dysrhythmia encountered in practice. It is currently estimated that AF affects approximately 2% of the general population; however, the ...

Atrial fibrillation is a cardiac arrhythmia in which the upper chambers of the heart the atria beat irregularly and, often, rapidly. The condition occurs as a consequence of uncoordinated ...

Consumer-grade smartphone-paired devices and smartwatches have very high sensitivity and specificity for atrial fibrillation. The specificity for arrhythmias with regular R-R intervals is very poor.

The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).

Atrial fibrillation (AFib) is the most common form of irregular heartbeat (arrhythmia). People with AFib have many treatment options, including medications and medical procedures. However ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study.